Senseonics (SENS) investor relations material

Product differentiation and market

• Eversense uses a physician-inserted sensor designed to remain in place for 365 days, unlike replaceable transcutaneous CGMs; insertion requires a clinical visit.

• Management cited reduced skin irritation and compression lows, plus iCGM status for pump connectivity; 90% of new patients switch from another CGM.

• The CGM market was estimated at $15B in 2026, with 11M users; management cited high-double-digit market CAGR.

Commercial momentum and access

• Q3 revenue was $19.6M, up 140% YoY; 2026 growth was tracking near 100%, with growth driven by new patients switching from competing products.

• About 60% of new patients came through DTC marketing and 40% through HCP referrals; U.S. sales represented 85% of revenue and Europe 15%.

• Eon Care had about 100 contracted nurses supporting insertions, with plans to expand to ~120 in the coming months and hundreds as coverage grows.

• Retention rose from 75% after the first sensor to 85% from the second to third, then above 90% from the third sensor onward.

• CMS reimbursement was cited as 40%-50% higher; about 60% of product volume used bundled payment, avoiding DME distributor margin and pharmacy-benefit reductions.

Pump partnerships and clinical results

• twiist from Sequel Med Tech launched earlier in 2026 with stronger-than-anticipated acceptance; Beta Bionics partnership was announced, with launch expected the following week.

• Eversense users had about 66% time in range, rising to 76% with the Sequel pump; management described the combined result as the highest published among integrated systems.

• Management expects at least two additional pump partnerships by 2028; current partners are expected to support the Freedom product first, with new partners potentially integrating during 2027.